Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | LMNA | P02545 | 5/20 | 0.63 |
| ▸ | NOS1 | P29475 | 3/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13288378 | 0.91 | MAPT (0.63) | MAPTLMNANOS1CYP3A4ALOX15 | |
| SCHEMBL13288379 | 0.86 | MAPT (0.63) | MAPTLMNANOS1CYP3A4ALOX15 | |
| SCHEMBL27975732 | 0.83 | MAPT (0.70) | MAPTLMNANOS1CYP3A4ALOX15 | |
| SCHEMBL3484765 | 0.81 | KDM4E (0.59) | MAPTLMNACYP3A4KDM4EPDE7A | |
| SCHEMBL2933011 | 0.79 | NOS1 (0.52) | MAPTLMNANOS1CYP3A4ALOX15 | |
| SCHEMBL271522 | 0.79 | MAPT (1.00) | MAPTLMNANOS1CYP3A4ALOX15 | |
| SCHEMBL29394925 | 0.79 | MAPT (1.00) | MAPTLMNANOS1CYP3A4ALOX15 | |
| SCHEMBL3485196 | 0.79 | KDM4E (0.58) | MAPTNOS1KDM4EPDE7AMAOB | |
| SCHEMBL6725914 | 0.78 | PDE7A (0.66) | MAPTLMNACYP3A4KDM4EPDE7A | |
| SCHEMBL27671367 | 0.77 | MAPT (0.97) | MAPTLMNANOS1CYP3A4ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-01-07 | — | — | US | disclosed |
| CN-101611041-A | Condensed heterocyclic compouds | TAKEDA PHARMACEUTICAL (JP) | 2009-12-23 | — | — | CN | disclosed |
| EP-2103620-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004238-A1 | FUSED HETEROCYCLIC COMPOUND | ERBB2, ROS1, FLT3 | MAPT 4025/4885LMNA 4738/4885NOS1 420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.